Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity.

ABSTRACT:

Background

Immune-stimulatory agents, like agonists of the innate immune receptor RIG-I, are currently tested in clinical trials as an intratumoral treatment option for patients with unresectable melanoma, aiming to enhance anti-tumor T cell responses. Switching of melanoma toward a dedifferentiated cell state has recently been linked to T cell and therapy resistance. It remains to be determined whether RIG-I agonists affect melanoma differentiation, potentially leading to T cell resistance.

Methods

Patient metastases-derived melanoma cell lines were treated with the synthetic RIG-I agonist 3pRNA, and effects on tumor cell survival, phenotype and differentiation were determined. Transcriptomic data sets from cell lines and metastases were analyzed for associations between

SUBMITTER: Thier B 

PROVIDER: S-EPMC9196182 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature